CAH CARDINAL HEALTH INC
Wholesale-Drugs, Proprietaries & Druggists' Sundries · NYSE · SEC CIK 721371 · Fiscal year ends 06/30
Financial factors as of 2026-06-30 (FY2026), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY14.2%
TTM net income YoY9.8%
TTM EPS YoY12.1%
Revenue 3-yr CAGR7.4%
Net income 3-yr CAGR73.2%
Margins
Gross margin3.8%
Operating margin1.0%
Net margin0.7%
FCF margin1.8%
EBITDA margin1.4%
Returns
ROE—
ROA3.1%
ROIC (approx.)135.8%
Asset turnover4.61x
Leverage & solvency
Liabilities / assets104.8%
Debt / equity—
Current ratio0.88x
Interest coverage7.51x
Cash quality & payout
Operating cash flow / net income3.02x
Accruals ratio-6.3%
Payout ratio28.6%
Capex / revenue0.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-09-30 | 2026Q22025-12-31 | 2026Q12025-09-30 | 2025Q4*2025-06-30 | 2025Q32025-03-31 | 2025Q22024-12-31 | 2025Q12024-09-30 | 2024Q4*2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $67.51B | $65.63B | $64.01B | $60.16B | $54.88B | $55.26B | $52.28B | $59.71B |
| Cost of revenue | $64.92B | $63.23B | $61.69B | $57.96B | $52.76B | $53.32B | $50.38B | $57.85B |
| Gross profit | $2.60B | $2.40B | $2.32B | $2.20B | $2.12B | $1.94B | $1.90B | $1.85B |
| SG&A expense | $1.59B | $1.50B | $1.46B | $1.48B | $1.31B | $1.31B | $1.28B | $1.24B |
| Operating income | $753.00M | $707.00M | $668.00M | $428.00M | $730.00M | $549.00M | $568.00M | $408.00M |
| Interest expense | $73.00M | $88.00M | $80.00M | $74.00M | $74.00M | $35.00M | $32.00M | -$4.00M |
| Pretax income | $688.00M | $630.00M | $598.00M | $384.00M | $665.00M | $511.00M | $541.00M | $391.00M |
| Income tax | $132.00M | $159.00M | $144.00M | $141.00M | $157.00M | $110.00M | $124.00M | $162.00M |
| Net income | $554.00M | $467.00M | $450.00M | $239.00M | $506.00M | $400.00M | $416.00M | $236.00M |
| EBITDA | $1.00B | $941.00M | $901.00M | $637.00M | $937.00M | $741.00M | $750.00M | $594.00M |
| EPS (basic) | 2.39 | — | 1.89 | — | — | — | 1.71 | — |
| EPS (diluted) | 2.38 | — | 1.88 | — | — | — | 1.70 | — |
| Dividends declared per share | 0.52 | 0.51 | 0.51 | 0.50 | 0.51 | 0.51 | 0.51 | 0.50 |
| Weighted avg. shares (diluted) | 233.00M | 237.00M | 239.00M | — | 241.00M | 243.00M | 245.00M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $5.26B | $2.78B | $4.59B | $3.87B | $3.33B | $3.81B | $2.87B | $5.13B |
| Short-term investments | — | — | — | — | — | — | — | $200.00M |
| Receivables | $14.54B | $13.66B | $13.77B | $13.24B | $12.67B | $12.37B | $11.78B | $12.08B |
| Inventory | $18.39B | $20.12B | $17.56B | $16.83B | $16.16B | $16.90B | $15.62B | $14.96B |
| Current assets | $40.99B | $39.23B | $38.54B | $36.37B | $34.59B | $35.76B | $32.91B | $34.88B |
| PP&E, net | $3.00B | $2.88B | $2.83B | $2.86B | $2.66B | $2.56B | $2.54B | $2.53B |
| Goodwill | $11.54B | $11.61B | $9.71B | $9.69B | $8.91B | $5.49B | $4.72B | $4.72B |
| Intangibles | $2.15B | $2.37B | $2.40B | $2.49B | $2.11B | $1.95B | $1.66B | $1.73B |
| Total assets | $59.54B | $58.08B | $55.23B | $53.12B | $49.87B | $47.00B | $43.06B | $45.12B |
| Current liabilities | $46.33B | $43.31B | $40.27B | $38.90B | $36.66B | $35.22B | $34.68B | $35.64B |
| Short-term debt | $1.89B | $680.00M | $52.00M | $550.00M | $543.00M | $544.00M | $940.00M | $434.00M |
| Long-term debt | $6.93B | $8.35B | $8.98B | $7.98B | $7.14B | $7.06B | $4.22B | $4.66B |
| Total debt | $8.81B | $9.03B | $9.03B | $8.53B | $7.68B | $7.61B | $5.16B | $5.09B |
| Total liabilities | $62.41B | $60.78B | $57.96B | $55.76B | $51.77B | $49.92B | $46.34B | $48.33B |
| Shareholders' equity | -$3.02B | -$2.88B | -$2.88B | -$2.78B | -$2.95B | -$2.99B | -$3.28B | -$3.21B |
| Net debt | $3.55B | $6.25B | $4.44B | $4.65B | $4.35B | $3.80B | $2.30B | -$41.00M |
| Cash flow statement | ||||||||
| Operating cash flow | $1.40B | $686.00M | $973.00M | $1.53B | $2.92B | -$400.00M | -$1.65B | $2.08B |
| Capital expenditure | $157.00M | $131.00M | $108.00M | $232.00M | $126.00M | $99.00M | $90.00M | $193.00M |
| Free cash flow | $1.24B | $555.00M | $865.00M | $1.29B | $2.79B | -$499.00M | -$1.74B | $1.88B |
| Investing cash flow | -$251.00M | -$1.98B | -$142.00M | -$1.63B | -$2.90B | -$976.00M | -$88.00M | $166.00M |
| Financing cash flow | -$742.00M | -$519.00M | -$110.00M | $656.00M | -$507.00M | $2.33B | -$540.00M | -$859.00M |
| Depreciation & amortization | $247.00M | $234.00M | $233.00M | $209.00M | $207.00M | $192.00M | $182.00M | $186.00M |
| Stock-based compensation | $109.00M | $31.00M | $93.00M | $153.00M | $32.00M | $30.00M | $30.00M | $33.00M |
| Dividends paid | $126.00M | $122.00M | $129.00M | $120.00M | $124.00M | $122.00M | $128.00M | $122.00M |
| Share buybacks | $500.00M | $383.00M | $375.00M | $0 | $375.00M | $15.00M | $375.00M | $0 |
Free plan shows the latest 8 periods; Pro shows all 74 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.